![]() |
|
|
Department of Internal Medicine, University of Oulu, Kajaanintie 50, FIN-90220 Oulu, Finland and Biocenter Oulu, University of Oulu, Kajaanintie 52, FIN-90220 Oulu, Finland; and * National Public Health Institute (KTL), Mannerheimintie 166, FIN-00300, Helsinki, Finland
2To whom correspondence should be addressed. .
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: homocysteine folate diet methylenetetrahydrofolate reductase methionine synthase humans
| INTRODUCTION |
|---|
|
|
|---|
An important genetic determinant of the plasma tHcy concentration is a
common polymorphism of the MTHFR gene (16)
. This defect
results from a C to T mutation at the nucleotide position 677 in DNA
(17)
, which reduces the basal activity of the enzyme by
50% (18)
. Homozygosity for the T677 allele of the MTHFR
gene is associated with elevated plasma tHcy concentrations
(16
,19)
. Although some studies have recently focused on
the influence of natural folate on the plasma tHcy concentration
(5
8)
, the effects of gene mutations on the
responsiveness of serum folate and plasma tHcy to increased dietary
folate have not been determined. Previously, we studied the influence
of a high dietary intake of natural folate on the concentrations of
serum folate and plasma tHcy in a controlled crossover diet
intervention (20)
. In the current study, we determined the
role of the gene polymorphisms of MTHFR, CBS and MS in the diet
responsiveness of serum folate and plasma tHcy.
| SUBJECTS AND METHODS |
|---|
|
|
|---|
The study subjects were healthy female volunteers who were working at the University Hospital of Oulu. Of the 86 women screened, 37 were eligible for the study. The subjects were eligible for inclusion if they fulfilled the following criteria: 1) no gastrointestinal, renal or hepatic disease; 2) normal blood glucose and lipid concentrations; 3) body mass index (BMI) between 20 and 29 kg/m2; 4) no alcoholism; 5) not a current smoker; 6) no use of supplemental vitamins and/or minerals for at least 6 mo before the onset of the study; and 7) no food allergy. Pregnant and lactating women were excluded from the study. Six subjects were using oral contraceptives, and three subjects were using postmenopausal estrogen/progestin supplementation. The study was carried out in accordance with the instructions of the Declaration of Helsinki. Informed consent was obtained from each participant. The study was approved by the Ethical Committee of the Faculty of Medicine, University of Oulu.
Study design.
This crossover study consisted of a 2-wk baseline period and two 5-wk study periods (low folate diet and high folate diet) with a 3-wk washout period in between. During the baseline and washout periods, the subjects consumed their habitual diets. At the end of the baseline period, the subjects were randomly assigned to two groups. Half of the subjects (n = 18) first consumed a low folate diet followed by a high folate diet, whereas the other half (n = 19) consumed the diets in the reverse order.
Diets.
Both diets were designed on the basis of the regular hospital meals (a 5-wk menu) and contained conventional foods and beverages. A basic days menu included breakfast, lunch, afternoon snack, dinner and evening snack. Breakfast was based on bread and/or breakfast cereals and low fat milk products. For lunch and dinner, warm dishes of meat, poultry or fish together with potatoes, pasta or rice were served. Lunch and dinner also included a dessert. The afternoon snack contained a low fat cake and coffee or tea, and the evening snack consisted of bread and cheese. The foods were prepared, packaged and delivered to the subjects by the hospital kitchen (University Hospital of Oulu, Oulu, Finland). On working days, the lunches and dinners were served at the hospital cafeteria. The participants could also take the packaged dinner home. On weekends, the subjects were able to eat the lunches and dinners at the hospital cafeteria or take the packaged weekend meals home on Friday. Other foodstuffs, such us bread, milk and fruit, were delivered to the subjects twice a week.
Both study diets were energy balanced and designed to be low in dietary
cholesterol (<200 mg/d) and saturated fat (
10% of total energy
intake). In both diets, the quantity and quality of dietary fat was
controlled by using low fat meat and dairy products, low fat cooking
methods, and vegetable oil and margarine. The low folate diet contained
one serving of both fresh vegetables and fresh fruit or fruit juice per
day. The intake of dietary folate with the low folate diet was designed
to be 200 µg/d. The intakes of vitamins B-6 and B-12
as well as other nutrients during the low folate diet period were
designed to meet the Nordic nutrition recommendations
(21)
.
Dietary folate was increased in the high folate diet by increasing the
consumption of fresh vegetables, citrus fruits and berries. At
breakfasts during the high folate diet period, the subjects ate
30 g
of fresh pepper and a piece of fruit, e.g., orange or kiwi, or 125 mL
of juice in addition to whole-grain bread, breakfast cereals and
low fat milk products. The high folate lunch included
100150 g of
salad from carrots, cauliflower or cabbage, for example, and
100 g
of steamed vegetables, e.g., broccoli, peas, carrots or cauliflower in
addition to the basic diet. Fresh berries, e.g., strawberries or black
currants, were served as dessert. At dinner, approximately the same
amounts of fresh and steamed vegetables as at lunch were consumed. The
dessert at dinner consisted of either fresh berries or a piece of
fruit, e.g., orange or kiwi. At both lunch and dinner, 100 mL of orange
juice was consumed. In the evening, the subjects ate 30 g of red pepper and 125 mL of orange or pineapple juice together with whole
grain bread and low fat cheese. The high intake of vegetables, citrus
fruit and berries was designed to result in an average of 600
µg folate/d. Dietary intakes of other nutrients during
the high folate diet period were designed to meet the Nordic nutrition
recommendations (21)
.
The same experienced dietician (M.-L.S.) interviewed all of the participants concerning their eating and exercise habits and determined an isocaloric energy intake level for each. During the intervention, the participants weighed themselves daily before lunch, and their dietary energy intake was adjusted, when necessary, to maintain their body weight unchanged during the study. Alcohol consumption was determined at baseline by interviewing the subjects who were advised to restrict their use of alcohol to less than four drinks per week during the study. According to the subjects reports, the amount of alcohol consumed was negligible, and alcohol was therefore not included in the calculations of diets.
Laboratory methods.
At baseline, overnight fasting blood samples were drawn for the clinical chemistry tests and for the measurements of plasma tHcy and serum and RBC folate and serum vitamin B-12 concentrations, which were also measured at the end of both study periods. The concentrations of plasma tHcy and serum folate and vitamin B-12, but not RBC folate, were also measured at the end of the washout period.
Concentrations of serum and red blood cell folate and serum B-12 were
determined using the Quantaphase II B-12 and Folate Radioassays
(Bio-Rad Laboratories, Espoo, Finland). For folate, the intra- and
interassay CV were 5.68.6%, depending on the folate concentration.
For vitamin B-12, the intra- and interassay CV were < 3.3%. The
plasma tHcy concentration was analyzed by the immunofluorometric IMX
method (Abbott Laboratories, Chicago, IL) (22)
. The
interassay CV was 3.2%. The accuracy was ascertained by using a Nordic
quality assurance system, in which the mean bias for 7 sera was -3.5%
(23)
.
Genomic DNA was isolated from peripheral leukocytes isolated from
anticoagulated blood (EDTA) by using a salting-out method according
to Miller and co-workers (24)
. The analysis of the
C677T polymorphism in the MTHFR gene was investigated by polymerase
chain reaction (PCR) of a DNA fragment followed by restriction enzyme
digestion with Hinf I (18)
. The presence or
absence of the 844ins68 of the CBS gene was tested using PCR
amplification and digestion with the restriction enzyme Bsr
I (11)
. The A2756G mutation of the MS gene was
detected using PCR amplification and Hae III restriction
analysis (25)
. All of the enzymes used were provided by
Finnzymes (Espoo, Finland). The fragments of all three gene
polymorphisms were visualized on a UV transilluminator after
electrophoresis on a 3% low melting point agarose gel (3:1 NuSieve,
BioWhittaker Molecular Applications, Rockland, ME) containing nucleic
acid gel stain (GelStar, BioWhittaker Molecular Applications).
Dietary analyses.
Four-day diet records were completed during the baseline diet period after the first visit to our laboratory. The dietary intake during the study was analyzed from duplicate portions collected every day. The analyses were done in the Agricultural Research Center of Finland (Jokioinen, Finland). The intakes of folate and vitamins B-6 and B-12 during the study diets were calculated from the study menus using the Nutrica computer program (Social Insurance Institution, Helsinki, Finland) based on the Finnish nutrient database.
Statistical analyses.
Because the concentrations of serum and RBC folate and plasma tHcy were not normally distributed, logarithmic corrections were used in all statistical analyses. The changes in the concentrations of serum and RBC folate, serum vitamin B-12 and plasma tHcy between the low and high folate diets were calculated by subtracting the values of the low folate diet from those of the high folate diet. Students t test for paired samples was used to determine the differences in the concentrations of serum and RBC folate, serum vitamin B-12 and plasma tHcy between the diets.
The diet-induced changes in the serum folate and plasma tHcy concentrations and the effect of the genotypes of MTHFR, CBS and MS were tested with respect to the intraindividual variation during the diet intervention. This was done by using a layered design in the form of repeated measurements across time (ANOVA of repeated measurements). The top layer in the model was the between-subject layer, in which the effect of having a certain genotype was tested with respect to the interindividual variation. The bottom layer was the within-subject layer, in which the repeated measures for the diet periods (the baseline, low folate diet and high folate diet) were tested with respect to the variation from one dietary period to another. In addition, the differences in the concentrations of serum folate and plasma tHcy between the different genotypes of each gene were detected using either Students t test for independent samples (CBS and MS genes) or one-way ANOVA (MTHFR gene). After one-way ANOVA, Scheffés test was used as the post-hoc test. The differences were considered significant at the 5% level. The SPSS software 9.0 (SPSS, Chicago, IL) was used in the statistical analyses. The values are expressed as means ± SD, unless otherwise stated.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
In our study, the serum folate concentrations of the subjects with the genotypes C/C, C/T and T/T of the MTHFR were similar at baseline. The dietary intake of folate at baseline was not low, which may explain in part the lack of difference in the initial serum folate concentration among the MTHFR genotypes.
In a previous study (19)
, subjects homozygous for the T677
allele of the MTHFR gene had a higher plasma tHcy concentration when
plasma folate was in the lower range but not when plasma folate was
high. These researchers (19)
suggested that homozygous
subjects have a higher folate requirement for the regulation of plasma
tHcy. In our study, the subjects homozygous for the T677 allele showed
a good response of plasma tHcy to a high intake of natural folate, even
though they tended to have a lower response of serum folate than the
subjects with the genotypes C/T or C/C. Thus, our study does not
support the theory that the subjects homozygous for the T677 allele
need more folate to control the plasma tHcy concentration. On the other
hand, we used natural folate from food, which might affect the serum
folate and plasma tHcy concentrations differently than folic acid.
Also, we used a whole-diet approach, and other dietary components,
such as vitamins B-6 and B-12, may have
contributed to the increase in the serum folate concentration. However,
the calculated intake of these vitamins did not differ between the diet
periods, and the plasma concentration of vitamin B-12 did not change
during the study. Therefore, effects of vitamins B-6 and B-12 on plasma
tHcy are unlikely in the current study.
In addition to the MTHFR gene polymorphism, we detected the 68-bp
insertion of the CBS gene and the A2756G transition of the MS gene.
Both the presence of the 68-bp insertion of the CBS gene and the G2756
allele of the MS gene are associated with lower fasting levels of
plasma tHcy (14)
. Whether these gene mutations are
associated with the diet responsiveness has not been determined. In the
present study, we found no differences between the basal tHcy levels of
the different genotypes of either the CBS or the MS genes. The more
extensive decrease in the plasma tHcy concentration of the subjects
with the 68-bp insertion of the CBS gene is explained by the higher
plasma tHcy of those subjects during the low folate diet period than at
the baseline. However, the G2756 allele of the MS gene was associated
with a lower plasma tHcy and a larger decrease in plasma tHcy during
the low folate diet period compared with the subjects with the genotype
A/A.
In the present study, the duration of the diet periods was 5 wk
and the length of the washout period was 3 wk. The washout period was
quite short compared with the previous study (2)
testing
the effects of a low dose folic acid supplementation on the plasma tHcy
concentration. In that study (2)
, an 8-wk washout period
was not sufficient for blood folate and plasma tHcy concentrations to
return to the baseline concentrations. In the present study, the
subjects who initially consumed the high folate diet tended to have a
higher (P = 0.10) serum folate concentration during the
low folate diet period than at baseline. In addition, they tended to
have a lower (P = 0.07) plasma tHcy concentration
during the low folate diet period than at baseline. The differences and
the carryover effect were small and may have occurred by chance.
However, the relatively short washout period may have masked some of
the effects of the high folate diet in the present study.
The number of subjects in the present study was quite small. Therefore, the results should be considered as preliminary data. However, this study suggests that the diet response of plasma homocysteine may be genetically regulated. It was of particular interest that the plasma tHcy of the subjects homozygous for the T677 allele of the MTHFR gene responded well to a high intake of natural folate, resulting in similar plasma tHcy levels as in the genotypes C/T and C/C. Also, the presence of the G2756 allele of the MS gene was associated with a more extensive decrease in plasma tHcy and a lower plasma tHcy concentration during the high folate diet period. Whether the effects of these gene polymorphisms on the diet responsiveness of plasma homocysteine are similar in subjects with higher initial homocysteine levels remains to be established.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
3 Abbreviations used: BMI, body mass index; CBS,
cystathionine ß-synthase; MS, methionine synthase; MTHFR,
methylenetetrahydrofolate reductase; PCR, polymerase chain reaction;
tHcy, total homocysteine. ![]()
Manuscript received February 28, 2001. Initial review completed May 14, 2001. Revision accepted July 17, 2001.
| LITERATURE CITED |
|---|
|
|
|---|
1. Hankey G. J. & Eikelboom J. W. (1999) Homocysteine and vascular disease. Lancet 354:407-413.[Medline]
2.
Brouwer I. A., van Dusseldorp M., Thomas C.M.G., Duran M., Hautvast J.G.A.J., Eskes T.K.A.B. & Steegers-Theunissen R.P.M. (1999) Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. Am. J. Clin. Nutr. 69:99-104.
3.
Jacques P. F., Selhub J., Bostom A. G., Wilson P.W.F. & Rosenberg I. H. (1999) The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N. Engl. J. Med. 340:1449-1454.
4. Brönstrup A., Hages M., Prinz-Langenohl R. & Pietrzik K. (1998) Effects of folic acid and combinations of folic acid and vitamin B-12 on plasma homocysteine concentrations in healthy, young women. Am. J. Clin. Nutr. 68:1104-1110.[Abstract]
5.
Brouwer I. A., van Dusseldorp M., West C. E., Meyboom S., Thomas C.M.G., Duran M., van het Hof K. H., Eskes T.K.A.B., Hautvast J.G.A.J. & Steegers-Theunissen R.P.M. (1999) Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. J. Nutr. 129:1135-1139.
6.
Appel L. J., Miller E. R., Jee S. H., Stolzenberg-Solomon R., Lin P.-H., Erlinger T., Nadeau M. R. & Selhub J. (2000) Effect of dietary patterns on serum homocysteine. Circulation 102:852-857.
7.
Broekmans W.M.R., Klöpping-Ketalaars I.A.A., Schuurman C.R.W.C., Verhagen H., van den Berg H., Kok F. J. & van Poppel G. (2000) Fruits and vegetables increase plasma carotenoids and vitamins and decrease homocysteine in humans. J. Nutr. 130:1578-1583.
8.
Riddell L. J., Chisholm A., Williams S. & Mann J. I. (2000) Dietary strategies for lowering homocysteine concentrations. Am. J. Clin. Nutr. 71:1448-1454.
9.
Folsom A. R., Nieto F. J., McGovern P. G., Tsai M. Y., Malinow M. R., Eckfeldt J. H., Hess D. L. & Davis C. E. (1998) Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 98:204-210.
10. Kluijtmans L.A.J., van den Heuvel L.P.W.J., Boers G.H.J., Frosst P., Stevens E.M.B., van Oost B. A., den Heijer M., Trijbels F.J.M., Rozen R. & Blom H. J. (1996) Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am. J. Hum. Genet. 58:35-41.[Medline]
11. Tsai M. Y., Bignell M., Schwichtenberg K. & Hanson N. Q. (1996) High prevalence of a mutation in the cystathionine ß-synthase gene. Am. J. Hum. Genet. 59:1262-1267.[Medline]
12. Kluijtmans L.A.J., Boers G.H.J., Trijbels F.J.M., van Lith-Zanders H.M.A., van den Heuvel L.P.M.J. & Blom H. J. (1997) A common 844ins68 insertion variant in the cystathionine ß-synthase gene. Biochem. Mol. Med. 62:23-25.[Medline]
13. Tsai M. Y., Yang F., Bignell M., Aras Ö & Hanson N. Q. (1999) Relation between plasma homocysteine concentration, the 844ins68 variant of the cystathionine ß-synthase gene, and pyridoxal-5'-phosphate concentration. Mol. Genet. Metab. 67:352-356.[Medline]
14. Tsai M. Y., Bignell M., Yang F., Welge B. G., Graham K. J. & Hanson N. Q. (2000) Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine ß-synthase and A2756G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis 149:131-137.[Medline]
15.
Van der Put N.M.J., van der Molen E. F., Kluijtmans L.A.J., Heil S. G, Trijbels J.M.F., Eskes T.K.A.B., van Oppenraaij-Emmerzaal D., Banerjee R. & Blom H. J. (1997) Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinemia in neural-tube defects and vascular disease. Q. J. Med. 90:511-517.
16. Harmon D. L., Woodside J. V., Yarnell J.W.G., McMaster D., Young I. S., McCrum E. E., Gey K. F., Whitehead A. S. & Evans A. E. (1996) The common "thermolabile" variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q. J. Med. 89:571-577.[Abstract]
17. Goyette P., Frosst P., Rosenblatt D. S. & Rozen R. (1995) Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am. J. Hum. Genet. 56:1052-1059.[Medline]
18. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G.J.H., den Heijer M., Kluijtmans L.A.J., van den Heuvel L. P. & Rozen R. (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:111-113.[Medline]
19.
Jacques P. F., Bostom A. G., Williams R. R., Ellison R. C., Eckfeldt J. H., Rosenberg I. H., Selhub J. & Rozen R. (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93:7-9.
20. Tormala M.-L., Rantala M., Alfthan G., Aro A., Savolainen M. J. & Kesaniemi Y. A. (1999) Plasma homocysteine concentration is decreased by diet-induced change in serum folic acid level. Circulation 100:I-25 (abs.).
21. Nordic Nutrition Recommendation (1996) Scand. J. Nutr. 40:161-165.
22.
Shipchandler M. T. & Moore E. G. (1995) Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMX® Analyzer. Clin. Chem. 41:991-994.
23. Möller J., Christensen L. & Rasmussen K. (1997) An external quality assessment study on the analysis of methylmalonic acid and total homocysteine in plasma. Scand. J. Clin. Lab. Investig. 57:613-619.[Medline]
24.
Miller S. A., Dykes D. D. & Polesky H. F. (1988) A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16:1215.
25. Harmon D. L., Shields D. C., Woodside J. V., McMaster D., Yarnell J.W.G., Young I. S., Peng K., Shane B., Evans A. E. & Whitehead A. S. (1999) Methionine synthase D919G polymorphism is a significant determinant of circulating homocysteine concentrations. Genet. Epidemiol. 17:298-309.[Medline]
26.
Malinow M. R., Nieto F. J., Kruger W. D., Duell B. P., Hess D. L., Cluckman R. A., Block P. C., Holzgang C. R., Andersen P. H., Seltzer D., Upson B. & Lin Q. R. (1997) The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler. Thromb. Vasc. Biol. 17:1157-1162.
27. Guttormsen A. B., Ueland P. M., Nesthus I., Nygard O., Schneede J., Vollset S. E. & Refsum H. (1996) Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (>40 µmol/liter). The Hordaland Homocysteine Study. J. Clin. Investig. 98:2174-2183.
28. Nelen W.L.D., van der Molen E. F., Blom H. J., Heil S. G., Steegers E.A.P. & Eskes T.K.A.B. (1997) Recurrent early pregnancy loss and genetic-related disturbances in folate and homocysteine metabolism. Br. J. Hosp. Med. 58:511-513.[Medline]
29.
Nelen W.L.D.M., Blom H. J., Thomas C.M.G., Steegers E.A.P., Boers G.H.J. & Eskes T.K.A.B. (1998) Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J. Nutr. 128:1336-1341.
30. Van der Put N.M.J., Steegers-Theunissen R.P.M., Frosst P., Trijbels F.J.M., Eskes T.K.A.B., van den Heuvel L. P., Mariman E.C.K., den Heyer M., Rozen R. & Blom H. J. (1995) Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346:1070-1071.[Medline]
31.
Omenn G. S., Beresford S.A.A. & Motulsky A. G. (1998) Preventing coronary heart disease. B vitamins and homocysteine. Circulation 97:421-424.
This article has been cited by other articles:
![]() |
Z. Zhang, Q. Shi, Z. Liu, E. M. Sturgis, M. R. Spitz, and Q. Wei Polymorphisms of Methionine Synthase and Methionine Synthase Reductase and Risk of Squamous Cell Carcinoma of the Head and Neck: a Case-Control Analysis Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1188 - 1193. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sharp and J. Little Polymorphisms in Genes Involved in Folate Metabolism and Colorectal Neoplasia: A HuGE Review Am. J. Epidemiol., March 1, 2004; 159(5): 423 - 443. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N Ames, I. Elson-Schwab, and E. A Silver High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms Am. J. Clinical Nutrition, April 1, 2002; 75(4): 616 - 658. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||